Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pvs25 DNA vaccine
- Development stage
- Preclinical
- Lead developer
- George Washington University
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
Pvs25 DNA vaccine is a transmission-blocking vaccine (TBV) candidate designed to prevent the transmission of *Plasmodium vivax* malaria. It consists of a plasmid DNA vector encoding the Pvs25 antigen, a highly conserved 25 kDa ookinete surface protein of *P. vivax*. When administered, the vaccine induces host cells to express the Pvs25 antigen, eliciting a robust humoral immune response. When a mosquito feeds on an immunized individual, the ingested anti-Pvs25 antibodies target the Pvs25 protein on the surface of the parasite's ookinetes within the mosquito midgut, thereby preventing the development of oocysts and interrupting the malaria transmission cycle. The vaccine has been evaluated in preclinical studies, often delivered via in vivo electroporation to enhance immunogenicity.
- Other names
- Plasmodium vivax ookinete surface protein 25 DNA vaccinePvs25 DNA-based vaccinePvs-25 DNA-based vaccinePvs 25 DNA-based vaccine
02
Targets
Pvs25 (Plasmodium vivax ookinete surface protein 25)
Beyond the preview
Go deeper on Pvs25 DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pvs25 DNA vaccine.